Marketing Information – AM Biotech

AM Biotech Wins Prestigious National Innovation Award, Pioneering Bio-Pulsed Exosome Research

ambiotechadmin — Fri, 03 Jan 2025 08:09:03 +0000

AM Biotech, a pioneering force in bio-pulsed exosome research, has been honored with the 21st National Innovation Award. This is a high commendation for AM Biotech’s long-standing dedication to research and innovation in the field of bio-pulsed exosomes.

AM Biotech’s groundbreaking “Cross-generational Bio-Pulse Exosome Application Platform”, which was awarded the National Innovation Award, can significantly reduce product development time and cost. Leveraging this platform, the company successfully launched Exo Giov in 2021, a cosmetic product harnessing the power of bio-pulsed exosomes for beauty and hair care. Additionally, AM Biotech is in the advanced stages of developing exosome-based treatments for a wide range of diseases, including menopause, ophthalmic disorders, otology, periodontitis, joint diseases, and chronic kidney disease.

Bio-Pulse Activation Technology

AM Biotech’s patented bio-pulse activation technology empowers the company to develop and produce high-quality bio-pulsed exosomes. Compared to conventional exosomes, AM Biotech’s exosomes exhibit significantly enhanced efficacy, with a 202% increase in protein content and a 188% increase in miRNA content. These enhancements make them highly effective in promoting cell repair and tissue regeneration.

Cross-generational Bio-Pulse Exosome Application Platform

This innovative platform is built upon AM Biotech’s patented bio-pulse activation technology and three other core technologies:

Bio-Pulse Activation Technology: Exosomes produced using this technology exhibit several to dozens of times greater efficacy in treating diseases, enhancing beauty, and promoting hair growth compared to conventional exosomes.
High-efficiency exosome production technology: Enables storage at room temperature.
Exosome Ultra-Purification Extraction Technology: Achieves a purity level of 99.99%.
Advanced Mass Production Process: Ensures consistent product quality.

AM Biotech Unveils Patented Bio-Pulsed Technology at Industry Forum

ambiotechadmin — Mon, 16 Dec 2024 09:01:45 +0000

AM Bio Tech’s “Patented Bio-Pulsed Technology Forum” held on December 15, 2024, successfully concluded. The event delved deep into the groundbreaking innovation behind Patented Bio-Pulsed Technology, shedding light on its mechanisms and providing compelling evidence of its effectiveness in skin rejuvenation and hair restoration.

The forum attracted a distinguished audience of medical aesthetics, beauty, and hair care professionals who were eager to learn more about this cutting-edge technology and its potential applications. Attendees gained valuable insights into the technology’s clinical efficacy, making it a compelling choice for their product offerings.

Dr. Huang Chi-Chia, President of the Chinese Society of Cosmetic Surgery and Anti-aging Medicine, emphasized the growing significance of Patented Bio-Pulsed Technology in the medical aesthetics industry. “This technology is not only innovative in its scientific underpinnings but also delivers tangible results in clinical practice,” he remarked. “It offers a comprehensive solution for both beauty and hair restoration.”

Scientific Validation and Clinical Success

Dr. Richard Hsieh, Chairman of AM Bio Tech highlighted AM Bio Tech’s unique patented bio-pulsed technology, which produces exosome medical raw materials with a purity of up to 99.99%. This exceptional purity translates into significantly enhanced collagen, elastin, and fibroblast production, as well as hair follicle stimulation compared to conventional exosomes. Moreover, AM Bio Tech’s technology allows for room temperature storage, expanding the applications of exosome-based hair care and skincare products.

Independent testing conducted by SGS further solidified the technology’s efficacy. The results revealed that 100% of participants experienced increased collagen levels and more even skin tone, while 97% reported increased hair density and stronger hair roots. These remarkable outcomes are attributed to AM Bio Tech’s Patented Bio-Pulsed Technology, which enables exosomes to interact with the skin and scalp more effectively.

Real-world Applications

Dr. Wang Si-ching of Nice Clinic shared her team’s clinical experience in utilizing Patented Bio-Pulsed Technology to treat skin aging and presented impressive before-and-after photos. Similarly, Dr. Tsai Zong-hua of Ferrari Clinic, a renowned expert in hair growth, showcased the clinical application of exosomes in hair regeneration, offering hope to individuals suffering from hair loss.

Regulatory Clarity

To ensure the safe and legal use of exosome products, the Taiwan Food and Drug Administration (TFDA) has established specific regulations for exosome cosmetics. During the forum, Yang Zi-yun from the TFDA’s Medical Devices and Cosmetic Division provided a detailed explanation of these regulations, including sales requirements for exosome products and the mandatory individual review process for human exosome raw materials.

Leading the Way in Exosome Innovation

As a pioneer in Induced bio-pulsed exosomes, AM Bio Tech is committed to further advancing research in this field. Beyond medical aesthetics, the company aims to develop innovative exosome-based products for various medical applications, including gynecology, dentistry, ophthalmology, nephrology, orthopedics, otolaryngology, and wound healing. AM Bio Tech is dedicated to bringing these products to the global market, improving the lives of people worldwide.

AM Biotech joins forces with PITDC to advance biotech innovation and expand into the trillion-dollar pharmaceutical market.

ambiotechadmin — Tue, 10 Sep 2024 02:03:14 +0000

Source: https://eyeontw.com/

With outstanding R&D achievements and impressive revenue performance, Ascension Medical Biotechnology (AM BioTech) has formed a partnership with the Medical and Pharmaceutical Industry Technology and Development Center (PITDC) to launch multiple biotech projects and enter the trillion-dollar pharmaceutical market 3

Ascension Medical Biotechnology (AM BioTech), a leading domestic company specializing in exosome functional induction technology and a pioneer in exosome applications for beauty and hair growth, announced on August 30, 2024, its partnership with Medical and Pharmaceutical Industry Technology and Development Center (PITDC) through a “Pharmaceutical Project Cooperation Development Agreement.” This collaboration marks the official launch of several biotech and pharmaceutical development projects, as AM BioTech ventures into the trillion-dollar pharmaceutical market.

Leveraging its exclusive international patent for bio-pulsed technology, AM BioTech has applied this innovation to various medical and cosmetic research areas. The first commercial product utilizing this technology is ExoGiov, the world’s first exosome designed specifically for skin rejuvenation and hair growth. Unlike non-induced exosomes (Naive Exosomes), ExoGiov has achieved international recognition with an INCI certification in 2022. Its remarkable effectiveness, unique market position, and ease of use have led to significant revenue growth. The product, available in lyophilization powder, liquid, and skincare formulations, can be stored at room temperature, reflecting the company’s impressive performance within just three years of its establishment.

Dr. Richard Hsieh, Chairman of AM BioTech, stated that in addition to its applications in beauty and hair growth, the bio-pulsed technology is also being explored for potential pharmaceutical uses in obstetrics and gynecology, dentistry, ophthalmology, nephrology, orthopedics, otolaryngology, and major wound repair. Preclinical efficacy tests have been completed, and most animal trials are finalized, showing promising potential to address unmet medical needs in these fields. The company is actively positioning its international patents and will soon publish four international research papers.

Ensuring legal compliance and product development in both beauty and pharmaceutical sectors remains a core principle for AM BioTech. The company will adhere to international pharmaceutical regulations as it embarks on developing medical projects. The PITDC, renowned for its expertise in pharmaceutical development and regulatory affairs, will collaborate closely with AM BioTech. After extensive discussions and planning between both teams, the agreement will officially commence in September 2024. This partnership signifies a new milestone for AM BioTech as it enters the biotech pharmaceutical development arena.

Dr. Mu-Huan Su, Chairman of the PITDC, emphasized that the center’s mission is to assist domestic companies with pharmaceutical product development and guidance while facilitating communication among industry, government, academia, and research sectors. This approach aims to enhance the technical standards of the pharmaceutical industry, promote technological advancement, and achieve industry upgrading and internationalization. The PITDC and AM BioTech have been discussing this project for three years, focusing on pharmaceutical initiatives. Given Taiwan’s relatively small market, it can be challenging for local industries to invest in such R&D. However, AM BioTech’s commitment to substantial research in new indications and applications is highly commendable. This collaboration will not only upgrade but also internationalize Taiwan’s industry. We aim to accelerate AM Biotech’s key pharmaceutical ingredients, product development and launch by partnering with the PITDC research team. Our collaboration will address both domestic and international regulations, enhance quality management systems, and implement manufacturing technologies. This will reduce the risks of AM Biotech’s self-funded development, shorten time to market, and speed up integration into the international supply chain. The planned development will proceed in two stages, aiming to maximize the benefits of domestically produced high-value pharmaceutical products.

Dr. Richard Hsieh, Chairman of AM BioTech, concluded by expressing confidence that, with the combined efforts of both teams, preliminary results will soon be visible, and the commercialization of pharmaceutical products will follow. AM BioTech’s research achievements and patent strategy are well-planned, offering a competitive market advantage. With the PITDC’s support and the collaborative development plan, the launch of AM BioTech’s products in various pharmaceutical applications is anticipated to be imminent.

AM Biotech Bio-Pulsed Exosomes entered the top 5 finalists pioneering innovation “Estée Lauder (NIV) BRKTHRU VOICES Prize” at 2024 in-Cosmetics Global

ambiotechadmin — Thu, 09 May 2024 02:37:43 +0000

Source: https://eyeontw.com/

“Ascension Medical Biotechnology Co. Ltd.” (AM BIOTECH) is a Taiwan medical biotechnology research company, producer of patented technology Bio-Pulsed Exosomes (Extracellular Vesicles), it is a Global Cross-Generation Innovative Cosmetic Ingredient recognized and favored by the international market in Europe and America.

AM BIOTECH is the exhibitor at In-cosmetics Global (Paris, France from April 16 to April 18, 2024) for its patented Bio-pulsed Exosomes (Extracellular Vesicles) raw materials and related derivatives products. In-cosmetics Global is a leading international cosmetics tradeshow annually for worldwide network of personal care ingredients and cosmetic ingredient; the exhibition displays the best achievements in the global cosmetics industry and can be called the “Oscars Global event for the cosmetics industry”. For personal care & cosmetics ingredients exhibitors, suppliers & manufactures included outstanding top cosmetic raw material suppliers such as BASF, Croda, Ashland, Solvay, Evonik, etc., exhibiting their new generation of innovative cosmetic raw materials. Leading international cosmetics brands and manufacturers such as L’Oreal, Unilever, Procter & Gamble, Estee Lauder, Kenvue, LVMH, etc. they are looking for excellent innovative cosmetic raw materials that comply with international regulations as a new generation of cutting-edge cosmetics for development and application.

ExoGiov® is a Biochemical-pulsed exosome; developed by AM BIOTECH; specifically designed for facial beauty and hair health. It is a specific-pathogen-free (SPF) chicken embryonic mesenchymal cell-derived extracellular vesicles, which is complies with international standards and regulations acceptable worldwide (INCI: chicken embryonic mesenchymal cell-derived extracellular vesicles). The Bio-pulsed exosome with inducing activated function is a self-developed patented cosmetic ingredient in combined the key 4 pillars innovation of (Clinical breakthroughs, Product innovation, Ingredient innovation, Research and Biotechnology innovation); its excellent efficacy results surpass ordinary exosomes and common cosmetic ingredients. The results and efficacy data were also published in the international Journal of Molecular Science.

AM BIOTECH Biochemical-pulsed exosome was selected as one of the top five innovation cosmetics raw materials in the world at 2024 in-cosmetics Global by the Estée Lauder Company’s New Incubation Ventures (NIV) BRKTHRU VOICES Prize. Hence, it is not only AM BIOTECH has the honor with international affirmation in advance medical research & innovation; but also, the opportunity to expand the worldwide market internationally for ExoGiov® Biochemical Pulsed Exosomes in important professional facial beauty & haircare channels.

Dr. Richard Hsieh, Chairman and Founder of AM BIOTECH for his leading Biochemical Pulse Exosomes, he particularly emphasized that exosome manufacturers around the world are planning for globalization in the international market, and AM BIOTECH is no exception. Although South Korea, Japan and even Taiwan have opened to use human Cell-derived exosomes for cosmetic raw materials, but in order to be able to integrate with the international market, so that the products can go out of Taiwan and take a global view, they must comply with the cosmetics regulations of most mainstream international markets. It can be seen that there is no company that used human-derived exosomes has joined the 2024 In-cosmetics Global exhibition.

AM BIOTECH ExoGiov® exosome complies with international standards and regulations acceptable worldwide, which is specific-pathogen-free (SPF) chicken embryonic mesenchymal cell-derived extracellular vesicles, and the others ordinary exosomes are mostly plant-derived exosomes. Furthermore, ExoGiov® is the world’s only Bio-pulsed exosome raw material for inducing facial beauty and hair growth functions.

This innovation breakthrough is the core of ExoGiov® patented biochemical pulsed functional-inducing-exosome technology, it can precisely regulate the expression of miRNA genes to make it better than ordinary Exosomes and general cosmetic raw materials. The effectiveness of ExoGiov® are dozens of times more effective in facial beauty and hair health, such as collagen type I and type III, elastin, skin fibroblast proliferation, melanin degradation, and hair follicle cell proliferation. It has produced excellent results in all aspects.

AM BIOTECH’s latest research on promoting hair follicle cell proliferation, it was further found that Minoxidil (the active ingredient of Rogaine) has an 87% hair follicle cell proliferation rate and a 20% hair follicle cell proliferation rate with generally non-functional inducing exosomes. The hair follicle cell proliferation rate of AM BIOTECH BIO-Pulsed Exosomes is 113%, and its efficacy is very outstanding.

AM BIOTECH Bio-Pulsed Exosomes has innovation break through on this cosmetic application, the storage and the regulation limitation. ExoGiov® patented biochemical pulsed functional-inducing-exosome has the uniqueness of 99.99% high-purity exosomes and can be stored at room temperature, they comply with the international cosmetic regulations and banning exosomes derived from human cells in most countries. The exosomes are the uniqueness of 99.99% high-purity exosomes and can be stored at room temperature.Most of the exosomes currently on the market are need to be keep in frozen temperature or refrigerated in low temperature to ensure bioactivity, their application in the development and application of cosmetic products is very limited.

AM BIOTECH entered into the top five finalist’s breakthrough innovation cosmetics raw materials in the world for the Estée Lauder (NIV) BRKTHRU VOICES Prize at 2024 In-cosmetics Global. ExoGiov® BIO-Pulsed Exosomes demonstrates its development advantages in the international market, the Estée Lauder (NIV) Executive Officer Mr. Ryan J. Piela and his expert team also saw these advantages and characteristics of AM BIOTECH Biochemical-Pulsed Exosomes. This professional recognition from Estée Lauder company has also prompted many other international cosmetics brands and cosmetics ingredients distributor agents from various international countries to inquire about AM BIOTECH the exosomes business cooperation.

AM BIOTECH becomes the first Taiwan’s exosomes to enter the international market, the Glory of Taiwan. AM BIOTECH has officially launched the ExoGiov® Bio-pulsed exosomes in use and application in the cosmetics ingredient and LA EXO® related skincare & haircare products.

According to the EUROPE DIRECT CONTACT CENTRE Consultation Response: ExoGiov Comes from SPF Eggs and Does Not Fall under the Categories Mentioned in ANNEX II/419

ambiotechadmin — Thu, 21 Mar 2024 03:05:20 +0000

According to the EUROPE DIRECT CONTACT CENTER consultation response summary (full response attached):

All cosmetics related to animal sources and derived ingredients will be labeled ANNEX II/419. However, this is only for reference and not as a basis for restriction/prohibition.

Furthermore, according to cosmetics regulations (1223/2009), the responsible person must ensure the safety of cosmetics on the market and assume corresponding responsibilities when using or not using such ingredients, and demonstrate whether the entries indicated in CosIng are related to these ingredients.

The ingredient “chicken embryonic mesenchymal cell-derived extracellular vesicles” from ExoGiov comes from SPF (Specific Pathogen Free) chicken eggs and does not fall under the categories mentioned in ANNEX II/419. It also has a safety report from a third-party inspection company, ensuring its safety for use in cosmetics.

Europe Direct Contact Centre

Your Europe Direct reply no #3662921

Dear Mr S. H. Lee,

Thank you for contacting the Europe Direct Contact Centre.

We have consulted the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW). Please find below the answer to your question.

“CosIng has only informative value, it is not a legally binding instrument. In addition, entry II/419 refers to ‘Category 1 material and Category 2 material as defined in Articles 4 and 5 respectively of Regulation (EC) No 1774/2002 of the European Parliament and of the Council ( 3 ), and ingredients derived therefrom”. This is added for information purposes. And it does not service as a restriction/prohibition as such.

According to the Cosmetics Regulation (1223/2009), the responsible person must ensure the safety of the cosmetic product placed on the market and has the respective responsibility in using or not such ingredients in cosmetics and attest whether the entry indicated in CosIng is relevant to these ingredients or not.

We hope you find this information useful. Please contact us again if you have other questions about the European Union, its activities or institutions.”

We hope you find this information useful. Please contact us again if you have other questions about the European Union, its activities or its institutions.

With kind regards,
Europe Direct Contact Centre
We answer all questions about the EU

AM Biotech’s Unique Bio-pulsed Exosome, Backed by Patents, Shows Bright Prospects in the Global Market

ambiotechadmin — Fri, 19 Jan 2024 05:58:51 +0000

Source: https://eyeontw.com/

Ascension Medical Biomedical Technology Co., Ltd. (AM Biotech), a pioneer in the development of induced exosome, showcased its groundbreaking patented technology and introduced the new generation ExoGiov and LAEXO exosome skincare products during a press conference on January 18, 2024.

The event featured Dr. Wu Chung-Hsiun, former Chairman of the Taiwan Bio Industry Organization, and renowned dermatologist Dr. Chian-Yaw, Huang , the director of the Yawen Dermatology Clinic, alongside Dr. Hsieh Ju-sheng, Chairman of AM Biotech. Together, they unveiled the differences and advantages of AM Biotech’s bio-pulse induced exosomes compared to ordinary exosomes in both domestic and international markets. The discussion covered industry trends, technological innovations, and the legal and regulatory aspects of product application, redefining the market advantages and core competitiveness of bio-pulse induced exosomes.

Dr. Wu Chung-hsun, in his opening speech, emphasized the significance of exosomes in the future development of the regenerative medicine industry. He acknowledged AM Biotech’s Technology as an industry pioneer in bio-pulse induced exosome and expressed optimism about its development potential. He congratulated the company for securing patents in Taiwan and China. Additional international patents are expected to be acquired successively, paving the way for a promising international market presence.

During the conference, Dr. Hsieh Ju-sheng, Chairman of AM Biotech, shared the strategic layout of the “bio-pulse induced exosome Technology Platform.” The company has developed over a hundred types of Exosomes for regenerative medicine applications, all confirmed for initial efficacy through next-generation gene sequencing (NGS), quantitative polymerase chain reaction (qPCR), and cell viability tests. Collaborations with domestic teaching hospitals and institutions, such as the Tri-Service General Hospital/National Defense Medical Center Taiwan, are in progress. These collaborations involve animal testing, gearing up for upcoming clinical trials focused on regenerative materials and new drugs. With the continuous acquisition of international patents, AM Biotech’s Technology is well-positioned for international market expansion and has already engaged in discussions for collaborations in overseas markets.

In addition to the pharmaceutical development plan, Chairman Hsieh also highlighted the skincare product “ExoGiov” set to launch in 2023. Utilizing non-human source interstitial stem cells, it complies with international cosmetic INCI standards, making it a legally compliant cosmetic extracellular vesicle ingredient with the international market. With unique functionality induction and purification technology, ExoGiov has gained recognition from domestic dermatologists. Even major competitors in the international market, notably South Korea, are closely monitoring. The year 2024 is anticipated to be a remarkable year for AM Biotech in the international market.

Dr. Huang Chien-yao, a well-known dermatologist in Taiwan, shared insights on evaluating and selecting exosomes for cosmetic skincare products during the conference. Dr. Huang emphasized the importance of safety and legality in the evaluation process. While Taiwan’s Ministry of Health and Welfare is in the process of amending regulations of prohibit the use of human-derived cells, tissues, and their derivatives in cosmetics, international restrictions on human-sourced exosomes remain in place. Until regulatory amendments are enacted, the use of non-human source exosomes and compliance with international cosmetic INCI standards are essential for skincare product applications. Dr. Huang elaborated on the positive effects of exosomes in various skincare applications, including skin repair, scar reduction, and hair loss prevention.

Dr. Huang further explained that AM Biotech’s bio-pulse induced exosomes, developed through exclusive patented technology, demonstrate significantly better effects in promoting collagen, elastin, fibroblast proliferation, and hair follicle growth compared to ordinary exosomes. The efficacy has been published in international journals. Dr. Huang highlighted the unique advantages of ExoGiov, such as the production of exosomes with a particle count 1,900 times higher and purity reaching 99.99%, both achieved through the company’s proprietary process technology, allowing for storage at room temperature. This significantly enhances the application of extracellular vesicles in skincare products.

In conclusion, AM Biotech announced a collaboration with Emosoxe Biotech International L.L.C. from the United States to jointly develop the new generation LAEXO series of bio-pulsed skincare products, including essence, anti-wrinkle cream, mask, and hair care serum. The packaging design primarily incorporates English, reflecting an international brand direction. The exosome concentration and formula design have been upgraded to meet international high standards, aiming to provide consumers with a new and high-quality international skincare brand experience.

Chairman of AM Biotech Went to The 49th Annual Meeting of Taiwanese Dermatological Association (TDA) to Give A Special Lecture

ambiotechadmin — Sat, 30 Dec 2023 07:00:14 +0000

The 49th Annual Meeting of Taiwanese Dermatological Association (TDA) and the 8th Euro-Asian Association of Dermatovenereologists (EAAD) Congress were held on 8 Dec to10 Dec, 2024 at Kaohsiung, Taiwan.

This meeting, leading experts in skin diseases, a skin health, skin aesthetics, from USA, Japan, Korea, Australia, Europe, and several other countries will share their knowledge of skin biology discuss its translational significance. Clinical lectures by experts within and outside of our communities will be delivered every day, high-quality symposiums will hold to review the latest advances in the management in skin related research, and a discussion of creative uses of artificial intelligence and telemedicine in dermatology will be initiated.

Dr. Ju-Sheng Shieh, chairman of Ascension Medical Biotechnology Co., Ltd (AM Biotech), was invited by the conference organizers to deliver a special lecture on the third day of the conference during the research forum titled “The latest not least about hair.” His presentation, titled “Discussing the efficiency and mechanism of bio-pulsed exosomes in beauty and hair growth from the perspective of miRNA and genes,” was addressed to over 500 dermatologists and skincare & Beauty research experts from both domestic and international backgrounds.

In his presentation, Dr. Shieh first introduced the differences between the self-developed bio-pulsed exosoms and conventional exosome (Naiev Exosome). He highlighted the technological advantages and features of the patented bio-pulsed technology platform. Finally, he introduced the successfully commercialized bio-pulsed exosomes specifically designed for skincare and hair growth, known as ExoGiov. The preliminary efficacy of ExoGiov was confirmed through NGS next-generation gene analysis, QPCR quantitative polymerase chain reaction, and cell viability tests, revealing several important characteristics:

Derived from non-human source chicken embryonic mesenchymal stem cells from the laboratory with no specific disease source (SPF), and obtained international cosmetics certification (INCI), ensuring complete legality and compliance.
Collaboration with the Tri-Service General Hospital,Taiwan for IRB human cell testing, with results co-published in the International Journal of Molecular Sciences.
Efficacy reaching several times that of conventional exosomes, such as collagen and elastic protein proliferation rates exceeding 300%, fibroblast proliferation rates exceeding 50%, and follicle cell proliferation rates exceeding 120%. the all research findings and outstanding efficacy data have been published in “International Journal of Molecular Science”
AM Bio uses panted extraction and lyophilization technology, achieving the purity of 99.99%, and whether in liquid or freeze-dried powder form, ExoGiov can be used and stored at room temperature.

Dr. Shieh concluded by stating that ExoGiov, in addition to having international cosmetics INCI, utilizes non-human source mesenchymal stem cells, making it a fully legal and compliant for cosmetics in the international market. He emphasized the unique induction and purification technology, making ExoGiov stand out with advantages such as high purity and room temperature storage. These qualities have attracted attention from international markets such as Europe, the United States, China, South Korea, and Japan. ExoGiov can be applied in the development of skincare and hair care products, positioning it as a noteworthy focus in the new generation of cosmetic ingredient.

Bio-Pulsed Exosome with innovative patented technology from AM Biotech to restore health and beauty

ambiotechadmin — Wed, 29 Nov 2023 02:10:00 +0000

News Source: The Eye On Taiwan

Ascension Medical Biotechnology company(AM Biotech) from Taiwan focusing on the research and development of induced and specific functional exosome. At the seminar on innovative technologies and applications of bio-pulsed exosome on November 19, With “innovative technology”, As the theme, Dr. Shieh, chairman of AM biotech and inventor of bio-pulsed exosome technology, invited exosome research experts, including Professor Shen Tanglong, director of Biotechnology Center of Taiwan University, who just won the “World Medical Award”, and two skin beauty and hair experts, Dr. Zhao Zhao ming, Dr. Liu Chun xi, cosmetics law expert, Ms. Jiang attended the meeting to give a keynote speech, From the aspects of academic research, technological innovation, product application and regulations, Attracting more than 200 many domestic medical and beauty clinics and cosmetics brand related businesses to attend the meeting, Discuss the hottest topic of regenerative medical research, “Exosome” in 2023. This seminar for participants to fully understand the exosome and induced exosome magic efficacy and mechanism of action , and further understand AM biotech’s exclusive bio-pulsed patent technology and it’s developed bexosome on the technology uniqueness, and how to legal compliance selection and application of exosome in medical beauty and cosmetics personal care product development,

At the beginning of the seminar, Dr. Wu Zhong xun, president of Taiwan Biological Industry Association, Dr. Chen Heng de, former CEO of Medical Inspection Center, and Professor Chen Min hui, vice President of Medical College of Taiwan University were also invited to deliver speeches, Chairman Wu said that regenerative medicine is one of the key development points of Taiwan’s biotechnology industry in recent years, has now advanced from the era of cell therapy to the era of the development of exosome technology, In recent years, exosome research has also shone brightly in the field of global medical research, more than 200 international clinical studies, Exosomes, whether used as clinical diagnostic reagents, drug carriers, or regenerative medicine research, are very important areas of biotechnology development. Now, with the promotion of the regenerative medicine regulation in Taiwan and the center of drug evaluation , Taiwan (CDE) also released the draft guiding principles for research and development strategies for the manufacturing control of extracellular vesicle in September, In order to cooperate with Taiwanese government to vigorously promote the exosomes from Taiwan in the world wild toward higher specifications, more international competitive direction.

Dr. Shieh, chairman of AM Biotech, said that in 2023, Exosome is the attention and development prospect in Taiwan and internationally are optimistic. Before this seminar, they also participated in the annual international cosmetic raw material Asia Pacific event, “In-Cosmetic Asia” held in Bangkok, Thailand. The professional buyers from world wild are concerned about the “exosome”, the shining star of cosmetic ingredient. Although exosomes from Korea started in the application field of cosmetic earlier than in Taiwan, However, in recent years, because the exosomes which they developed mostly use human cell sources, with most countries including Taiwan, to prohibit the use of human-derived cells and their derivatives as cosmetic ingredient. nBecause it cannot be used legally and compliantly, and it cannot be stored at room temperature, it greatly reduces the wide application of its products.

Therefore, in addition to letting participants know what bio- pulsed exosomes are. As Professor Shen, pointed out that the specific efficacy of induced exosome is far better than the ordinarily exosome without the induction. Different with the general exosome based products from worldwide, AM Biotech relies on its own patented bio-Pulsed technology to develop exosome “ExoGiov”, which is a specific induction product focusing on the application of skin beauty and hair growth. Through the cooperation with Tri-Services General Hospital of national defense medical college, Taiwan on the IRB human cell efficacy testing research. ExoGiov has outstanding data on several key indicators in skin application and hair growth, and its efficacy can reach dozens of times that of ordinary exosomes. For example, the proliferation ratio of collage and elastin can be more than 300%, the proliferation ratio of fibroblasts can be more than 50%, and the proliferation ratio of hair follicle cells can be more than 120%. The results have been published in the international academic journal International Journal of Molecular Sciences, and now we are also conducting human clinical trial for skin and hair growth in the Tri- Services General Hospital, Taiwan.

Two skin beauty and germinal specialist in the second half, also said many studies in the worldwide are pointed out that “ExoGiov in skin beauty and germinal application has its unique mechanism and efficacy. Therefore, it is even more important to choose legal and compliant exosomes to develop into products for use. After legal compliance, the next step is to evaluate the safety. After completing the safety evaluation, the next step is to evaluate the relevant efficacy research and actual use effects. ExoGiov is an exosome product that meets such standards. The actual application effect of ExoGiov is as ideal as its published literature data. Therefore, ExoGiov is very suitable for the development of skin beauty and hair health product applications and as a beauty and hair health treatment. Use on Finally, Ms. Jiang, a previous team leader of pharmaceutical & cosmetics advertising reviewer , share how to determine that cosmetics contain legal exosomes: First, confirm that “exosome” are clearly marked on the packaging of cosmetic products, rather than only a vague description in the advertisement. Second, ensure that the INCI (international name of the cosmetic ingredients) is listed in the list of cosmetic ingredients, such as Chicken Embryonic Mesenchymal Cell-Derived Extracellular Vesicles. Third, according to the regulations of DOH, it is confirmed that the components are cells from “non-human origin” (exosomes) derived from the above components. Finally, it is confirmed that the product has been logged in on the Product Information File (PIF) of Cosmetics.

In addition to providing medical beauty, beauty SPA, skin care and hair strengthening products with the exosome cosmetic raw material “ExoGiov” that complies with Taiwan and most international cosmetics regulations, AM Biotech is also moving towards the fields of medical materials and regenerative treatments. The development of some medical materials and drugs has entered the animal experiment stage. iAM Biotech will be the most anticipated exosome biotechnology company in Taiwan. Dr. Shieh, chairman of AM Biotech, hope that in the future, through more seminars and product application workshops, more people in the worldwide learn more about the various applications of bio-pulsed exosome, and their innovative technology will bring a healthy and beautiful future to the world.

The Key to Skin Repair: The Fantastic Bio-Pulsed Exosomes

ambiotechadmin — Sat, 30 Jul 2022 01:47:00 +0000

News Source: The Eye On Taiwan

Ascension Medical Biotechnology Co., Ltd. (abbreviation: AM BioTech) is the first in Taiwan and the second in the world to obtain “Non-Human Source Stem Cell Exosomes” certified by the International Cosmetic Ingredient (INCI), the company’s product name is ExoGivo^® Bio-pulsed Exosomes which can be stored at room temperature and added to cosmetics in compliance with laws and regulations. The experimental results showed that the effects on cell activation and proliferation are in evidence. Dr. Ju-Sheng Shieh, chairman of AM BioTech, said that using the exclusive patented extraction and bio-pulsed technology, stem cells are guided to produce exosomes with special functions, which greatly improves exosome efficacy. It has a fantastic effect in smoothening fine lines, firming skin, promoting skin whitening, and activating hair follicle cells.

Until exosome research won the Nobel Prize in Physiology or Medicine in 2013, greatly opening up many medical-related applications of exosomes. Many preclinical and clinical studies are currently being initiated to explore the application of exosomes to skin-related diseases. Therefore, exosomes have received increasing attention in dermatology research. As a family member of extracellular vesicles, exosomes are nanoscale structures secreted by cells and play a key role in regulating the physiological and pathological processes of the skin. Exosomes are primarily responsible for coordinating communication between cells and for transporting cellular components, including microRNAs, mRNA, DNA, lipids, metabolites, and proteins.

AM BioTech’s patented technology for purification and extraction of exosomes, no matter lyophilized powder or exosome reconstituted stock solution, can be stored and transported at room temperature. The particle number of exosomes in each gram of lyophilized powder can be reached as high number as 22 trillion. AM BioTech currently has two series of products, including ExoGivo^® Bio-pulsed Exosome and LA EXO^® Exosome High-Efficiency Revitalization Series, which have recently won the Taiwan Gold Brand and Chinese Excellence Award.

ExoGivo^® Bio-pulsed Exosome received the International Cosmetic Ingredient (INCI) Name and can be legally added to cosmetics. The product has been verified by Institutional Review Board (IRB) on human cells and has excellent effects on skin repair, collagen expression, elastin expression, and hair cell proliferation. It can be added to hair serum, essence, lotion, facial cream, facial mask, eye cream, and other products. The company will seek domestic and foreign cosmetics companies to cooperate in production.

LA EXO^® Exosome High-Efficiency Revitalization Series has added the stem cell exosomes in aesthetic medical grade essence and various skin care products, which were developed by AM BioTech to assist the American exosome company EMOSOXE. The products have been verified by IRB on human cells and have been shown to effectively repair the skin and promote skin brightening. LA EXO^® Exosome High-Efficiency Revitalization Series are the main products for end consumers and have the effects of skin whitening, fine lines smoothening, and hair root strengthening. It is expected to be launched for major aesthetic medical clinics and cosmetics distribution channels at the end of July.

The Emergent Role of Exosome Therapy in 2021

admin — Thu, 17 Mar 2022 05:21:11 +0000

Source: exosome.com

Exosomes are extracellular vesicles (EV) derived from endosomes, ranging in size from 30nm to 150nm. Exosomes can be secreted by many cells. In fact, all living cells use exosomes as communication mediators. Exosomes carry cell-specific proteins, lipids, and nucleic acids, which can be selectively absorbed by recipient cells. Although exosomes were discovered more than 30 years ago, it is only in recent years that the scientific community has begun to attribute a series of promising features of exosomes to them. Today, up to 18000 articles related to exosomes have been published on PubMed.gov, and a surprising number of articles released in the past five years accounted for 74%.

Marketing Information – AM Biotech

AM Biotech Wins Prestigious National Innovation Award, Pioneering Bio-Pulsed Exosome Research

Bio-Pulse Activation Technology

Cross-generational Bio-Pulse Exosome Application Platform

AM Biotech Unveils Patented Bio-Pulsed Technology at Industry Forum

AM Biotech joins forces with PITDC to advance biotech innovation and expand into the trillion-dollar pharmaceutical market.

Read Moreread more

AM Biotech Bio-Pulsed Exosomes entered the top 5 finalists pioneering innovation “Estée Lauder (NIV) BRKTHRU VOICES Prize” at 2024 in-Cosmetics Global

Read Moreread more

According to the EUROPE DIRECT CONTACT CENTRE Consultation Response: ExoGiov Comes from SPF Eggs and Does Not Fall under the Categories Mentioned in ANNEX II/419

Read Moreread more

AM Biotech’s Unique Bio-pulsed Exosome, Backed by Patents, Shows Bright Prospects in the Global Market

Read Moreread more

Chairman of AM Biotech Went to The 49th Annual Meeting of Taiwanese Dermatological Association (TDA) to Give A Special Lecture

Read Moreread more

Bio-Pulsed Exosome with innovative patented technology from AM Biotech to restore health and beauty

Read Moreread more

The Key to Skin Repair: The Fantastic Bio-Pulsed Exosomes

Read Moreread more

The Emergent Role of Exosome Therapy in 2021

Read Moreread more